Group 1 - The core viewpoint of the news is that Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.09%, reaching 89.20 yuan per share, with a total market capitalization of 7.992 billion yuan [1] - Ruimait specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea-hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund's Nord Small and Mid-Cap Mixed Fund holds 18,000 shares of Ruimait, accounting for 5.02% of the fund's net value, making it the fifth-largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 35.43%, ranking 1958 out of 8154 in its category [2] - The fund manager, Zhu Mingrui, has been in position for 3 years and 114 days, with the best fund return during his tenure being 25.82% [3]
瑞迈特股价涨5.09%，诺德基金旗下1只基金重仓，持有1.8万股浮盈赚取7.78万元